You are here: Industry Insights > toripalimab

News List

How is the progress of China’s domestically produced PD-(L)1 “going global”? Yefenghong/PharmaSources
November 23, 2023
Recently, Coherus BioSciences announced that the FDA has approved the launch of PD-1 antibody toripalimab (marketed jointly by Junshi Biosciences and Coherus) for use in combination with gemcitabine/cisplatin as a first-line treatment for advanced recurre
FDA's Approval was Postponed Again, Chinese Innovative Pharmaceutical Companies has Extended Their Businesses to the Middle East and North Africa PharmaSources
April 27, 2023
The export of domestic PD-1 is much more difficult than expected.The Middle East and North Africa has become a new choice for the export of domestic innovative pharmaceutical companies in the past two years.
Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting prnasia
June 02, 2021
Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 4th to 8th.
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy americanpharmaceuticalreview
March 26, 2021
Eucure Biopharma, a subsidiary of Biocytogen, announced its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injection (TUOYI®), has demonstrated encouraging anti-tumor activity in a ...
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences' Anti-PD-1 prnasia
March 23, 2021
Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injection ...
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S. prnasia
February 07, 2021
I-Mab announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors.
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab prnasia
February 04, 2021
Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®) ...
Junshi Biosciences gets US FDA Breakthrough Therapy Designation for Toripalimab to treat nasopharyngeal carcinoma expresspharma
September 14, 2020
Chinese firm, Junshi Biosciences announced that the US Food and Drug Administration (FDA) has recently granted Breakthrough Therapy designation (BTD) to Toripalimab for the treatment of nasopharyngeal carcinoma.
Junshi, Merck Collaborate on Head, Neck Cancer Treatment in China americanpharmaceuticalreview
June 11, 2020
Junshi Biosciences and Merck announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of anti-PD-1 mAb toripalimab (TUOYI®) in combination with Cetuximab (Erbitux®) ...
Sales of Toripalimab and Sintilimab Both Exceeded RMB300 Million PharmaSources/Xiaoyaowan
October 24, 2019
Junshi Biosciences’ toripalimab and Innovent’s sintilimab were successively approved in Dec. 2018, to become the first Chinese-produced anti-PD-1 monoclonal antibodies marketed.